Program
zanubrutinib
Also written as “Zanubrutinib”, “BGB-3111” and “BGB-3111 and Drug Cocktail”.
Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Large B-Cell, Diffuse · Lymphoma, Mantle-Cell · Waldenstrom Macroglobulinemia · Lymphoma, B-Cell, Marginal Zone, led by BeOne Medicines.
Drug pageZanubrutinib: every studyAll 146 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BeOne Medicines | 358 open or running | phase 4since Sep 5, 2025 | Jan 9, 2015 | Dec 31, 2026phase 3 · NCT04170283 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 21 earlier studies, Jan 9, 2015 to Nov 14, 2019.
- Jun 9, 2017Named zanubrutinibINNProposed as its International Nonproprietary Name in WHO's List 117 · before, BGB-3111
- Nov 18, 2019Phase 3 study in B-cell MalignanciesNCT04170283 · 955 enrolled · United States, Australia, China and more
- May 7, 2020Phase 2 study in COVID-19NCT04382586 · 63 enrolled · United States
- Jun 16, 2020Phase 1 study in Lymphoma, Large B-Cell, DiffuseNCT04436107 · 66 enrolled · China
- Jul 10, 2020Phase 1 study in HealthyNCT04470908 · 13 enrolled · United States
- Sep 9, 2020Phase 1 study in B-cell MalignanciesNCT04551963 · 26 enrolled · Australia
- Nov 18, 2020Phase 2 study in Lupus NephritisNCT04643470 · 177 enrolled · China
- Sep 27, 2021Phase 3 study in Lymphoma, FollicularNCT05100862 · 799 enrolled · United States, Argentina, Australia and more
- Sep 27, 2021Phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT05068440 · 65 enrolled · China
- Sep 16, 2022Phase 1 study in Healthy VolunteersNCT05547399 · 43 enrolled · United States
- Jan 23, 2023Phase 3 study in Primary Membranous NephropathyNCT05707377 · 178 enrolled · United States, Brazil, Canada and more
- Mar 2, 2023Phase 1 study in Healthy VolunteersNCT05767398 · 58 enrolled · United States
- Oct 3, 2023Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06073821 · 652 enrolled · United States, Australia, Austria and more
- Sep 5, 2025Phase 4 study in Waldenstrom MacroglobulinemiaNCT07169331 · 16 enrolled · China
- Dec 2, 2025Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT07277231 · 500 planned · United States, Australia, Brazil and more
Ahead
- Dec 31, 2026Primary completion: phase 3 study in B-cell MalignanciesNCT04170283
- Oct 2027Primary completion: phase 3 study in Primary Membranous NephropathyNCT05707377
- Jul 2028Primary completion: phase 3 study in Lymphoma, FollicularNCT05100862
- Oct 31, 2028Primary completion: phase 4 study in Waldenstrom MacroglobulinemiaNCT07169331
TargetBeta
“An inhibitor of Bruton's tyrosine kinase (BTK) ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule
Other programs on BTK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ibrutinibrule | Johnson & Johnson | phase 4 | 78 |
| acalabrutinibrule | AstraZeneca | phase 4 | 55 |
| pirtobrutinibrule | Eli Lilly | phase 4 | 30 |
| ritlecitinibrule | Pfizer | phase 3 | 42 |
| orelabrutinibrule | InnoCare Pharma | phase 3 | 27 |
| rilzabrutinibrule | Sanofi | phase 3 | 23 |
| evobrutinibrule | Merck KGaA, Darmstadt, Germany | phase 3 | 20 |
| fenebrutinib | Hoffmann-La Roche | phase 3 | 18 |
| nemtabrutinib | Merck | phase 3 | 16 |
| rocbrutinibrule | Lupeng Pharmaceutical | phase 3 | 15 |
| tirabrutinibrule | Gilead Sciences | phase 3 | 13 |
| birelentinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
Studies
All 35 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07277231Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Brazil and more | 3 | Recruiting | Feb 2031 | 500 |
| NCT07169331Waldenstrom Macroglobulinemia · China | 4 | Active, not recruiting | Oct 31, 2028 | 16 |
| NCT06073821Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more | 3 | Active, not recruiting | Feb 2032 | 652 |
| NCT05767398Healthy Volunteers · United States | 1 | Completed | Apr 28, 2023 | 58 |
| NCT05707377Primary Membranous Nephropathy · United States, Brazil, Canada and more | 3 | Active, not recruiting | Oct 2027 | 178 |
| NCT05547399Healthy Volunteers · United States | 1 | Completed | Dec 7, 2022 | 43 |
| NCT05100862Lymphoma, Follicular · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jul 2028 | 799 |
| NCT05068440Lymphoma, Large B-Cell, Diffuse · China | 2 | Completed | Mar 31, 2025 | 65 |
| NCT04643470Lupus Nephritis · China | 2 | Completed | Feb 26, 2024 | 177 |
| NCT04551963B-cell Malignancies · Australia | 1 | Completed | Feb 21, 2022 | 26 |
| NCT04470908Healthy · United States | 1 | Completed | Nov 10, 2020 | 13 |
| NCT04436107Lymphoma, Large B-Cell, Diffuse · China | 1 | Completed | Mar 28, 2024 | 66 |
| NCT04382586COVID-19 · United States | 2 | Completed | Feb 1, 2021 | 63 |
| NCT04170283B-cell Malignancies · United States, Australia, China and more | 3 | Active, not recruiting | Dec 31, 2026 | 955 |
| NCT04172246Leukemia, Lymphocytic, Chronic, B-Cell · Japan | 2 | Completed | May 10, 2023 | 55 |
| NCT04163783Healthy Volunteers · United States | 1 | Completed | Apr 18, 2017 | 6 |
| NCT04163523Healthy Volunteers · Australia | 1 | Completed | Jul 21, 2016 | 18 |
| NCT04116437Leukemia, Lymphocytic, Chronic, B-Cell · United States | 2 | Completed | Jan 9, 2026 | 96 |
| NCT04002297Lymphoma, Mantle-Cell · United States, Australia, Austria and more | 3 | Active, not recruiting | Apr 27, 2026 | 510 |
| NCT03734016Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more | 3 | Completed | Aug 8, 2022 | 652 |
| NCT03846427Lymphoma, B-Cell, Marginal Zone · United States, Australia, China and more | 2 | Completed | May 4, 2022 | 68 |
| NCT03561298Healthy Subjects · United States | 1 | Completed | Jun 7, 2018 | 18 |
| NCT03520920Lymphoma, B-Cell, Marginal Zone · China | 2 | Completed | Aug 28, 2020 | 41 |
| NCT03465059Hepatic Insufficiency · United States | 1 | Completed | Oct 19, 2018 | 29 |
| NCT03432884Healthy Volunteers · United States | 1 | Completed | Apr 16, 2018 | 40 |
| NCT03332173Waldenstrom Macroglobulinemia · China | 2 | Completed | May 8, 2019 | 44 |
| NCT03336333Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more | 3 | Active, not recruiting | May 7, 2021 | 590 |
| NCT03301181Healthy Volunteers: Asian, Non-Asian · United States | 1 | Completed | Nov 7, 2017 | 40 |
| NCT03206970Lymphoma, Mantle-Cell · China | 2 | Completed | Feb 15, 2019 | 86 |
| NCT03206918Recurrence · China | 2 | Completed | Jun 15, 2018 | 91 |
| NCT03189524Lymphoma, B-Cell · China | 1 | Completed | Aug 26, 2020 | 44 |
| NCT03145064Lymphoma, Large B-Cell, Diffuse · China | 2 | Completed | May 24, 2019 | 41 |
| NCT02795182Lymphoma · Australia, China | 1 | Completed | Dec 18, 2020 | 75 |
| NCT02569476Lymphoma · United States, Australia, Korea, Republic of | 1 | Completed | Sep 2, 2020 | 119 |
| NCT02343120B-cell Malignancies · United States, Australia, Italy and more | 2 | Completed | Mar 31, 2021 | 385 |
How it is read
Names in the registry
- “Zanubrutinib”, 30 entries
- “BGB-3111”, 2 entries
- “zanubrutinib”, 1 entry
- “BGB-3111 and Drug Cocktail”, 1 entry
- “BGB-3111 (Arm A)”, 1 entry
Codes read as this program: BGB3111.
Conditions, from the studies’ own filings
- Leukemia, Lymphocytic, Chronic, B-Cell, 7 studies
- Lymphoma, Large B-Cell, Diffuse, 3 studies
- Lymphoma, Mantle-Cell, 2 studies
- Waldenstrom Macroglobulinemia, 2 studies
- Lymphoma, B-Cell, Marginal Zone, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.